Ignite Creation Date:
2025-12-25 @ 3:55 AM
Ignite Modification Date:
2026-02-25 @ 9:41 PM
Study NCT ID:
NCT02327702
Status:
UNKNOWN
Last Update Posted:
2014-12-30
First Post:
2014-12-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients
Sponsor:
Asian-Pacific Alliance of Liver Disease, Beijing
Organization:
Study Overview
Official Title:
Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients
Status:
UNKNOWN
Status Verified Date:
2014-12
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates generic emtricitabine(FTC) efficacy and safety in Chinese naive pregnant chronic hepatitis B patients. Single group patients were enrolled to receive emtricitabine till 48 weeks after delivery.
Detailed Description:
Single group patients were enrolled to receive emtricitabine till 48 weeks after delivery, which include HBeAg positive and negative patients.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: